Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
Date: 2025-02-06
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, free movement of goods, market approval, medicinal product, withdrawal from the market








C_202500950EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/950


6.2.2025






Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
(C/2025/950)


Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2024, at their meeting on 23 September 2024:







Annex I

List of new marketing authorisations











Annex II

List of renewed marketing authorisations











Annex III

List of extended marketing authorisations











Annex IV

List of withdrawn marketing authorisations











Annex V

List of suspended marketing authorisations








ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2024:








EU-Number


Product


Country


Date of authorisation




EU/1/24/1805


Agilus


Iceland


26.6.2024




EU/1/24/1805


Agilus


Liechtenstein


31.5.2024




EU/1/24/1805


Agilus


Norway


31.5.2024




EU/2/24/306


Alcort


Liechtenstein


30.4.2024




EU/2/24/306


Alcort


Norway


27.6.2024




EU/1/24/1824


ALTUVOCT


Liechtenstein


30.6.2024




EU/1/24/1824


ALTUVOCT


Norway


25.6.2024




EU/1/24/1796


Apremilast Accord


Iceland


3.6.2024




EU/1/24/1796


Apremilast Accord


Liechtenstein


30.4.2024




EU/1/24/1796


Apremilast Accord


Norway


16.5.2024




EU/1/24/1815


Awiqli


Iceland


27.6.2024




EU/1/24/1815


Awiqli


Liechtenstein


31.5.2024




EU/1/24/1815


Awiqli


Norway


22.5.2024




EU/1/23/1777


Azacitidine Kabi


Iceland


12.1.2024




EU/1/23/1777


Azacitidine Kabi


Liechtenstein


31.1.2024




EU/1/23/1777


Azacitidine Kabi


Norway


15.1.2024




EU/2/23/303


Bovilis Cryptium


Iceland


5.1.2024




EU/2/23/303


Bovilis Cryptium


Norway


23.1.2024




EU/1/23/1787


Casgevy


Iceland


22.2.2024




EU/1/23/1787


Casgevy


Liechtenstein


29.2.2024




EU/1/23/1787


Casgevy


Norway


19.2.2024




EU/1/24/1806


Celldemic


Iceland


21.5.2024




EU/1/24/1806


Celldemic


Liechtenstein


30.4.2024




EU/1/24/1806


Celldemic


Norway


22.5.2024




EU/1/23/1769


Dabigatran etexilate Leon Farma


Iceland


18.3.2024




EU/1/23/1769


Dabigatran etexilate Leon Farma


Liechtenstein


29.2.2024




EU/1/23/1769


Dabigatran etexilate Leon Farma


Norway


26.3.2024




EU/1/24/1811


Dimethyl fumarate Accord


Iceland


16.5.2024




EU/1/24/1811


Dimethyl fumarate Accord


Liechtenstein


30.4.2024




EU/1/24/1811


Dimethyl fumarate Accord


Norway


26.4.2024




EU/1/24/1814


Dimethyl fumarate Mylan


Iceland


16.5.2024




EU/1/24/1814


Dimethyl fumarate Mylan


Liechtenstein


30.4.2024




EU/1/24/1814


Dimethyl fumarate Mylan


Norway


26.4.2024




EU/1/24/1810


Dimethyl fumarate Neuraxpharm


Iceland


17.5.2024




EU/1/24/1810


Dimethyl fumarate Neuraxpharm


Liechtenstein


30.4.2024




EU/1/24/1810


Dimethyl fumarate Neuraxpharm


Norway


26.4.2024




EU/2/24/307


DIVENCE PENTA


Liechtenstein


30.4.2024




EU/2/24/307


DIVENCE PENTA


Norway


11.6.2024




EU/2/24/310


DIVENCE Tetra


Liechtenstein


31.5.2024




EU/2/24/310


DIVENCE Tetra


Norway


3.6.2024




EU/1/24/1808


Emblaveo


Iceland


29.5.2024




EU/1/24/1808


Emblaveo


Liechtenstein


30.4.2024




EU/1/24/1808


Emblaveo


Norway


7.5.2024




EU/1/24/1819


Eribulin Baxter


Liechtenstein


30.6.2024




EU/1/24/1794


EXBLIFEP


Iceland


5.4.2024




EU/1/24/1794


EXBLIFEP


Liechtenstein


31.3.2024




EU/1/24/1794


EXBLIFEP


Norway


26.3.2024




EU/1/24/1802


FABHALTA


Iceland


25.6.2024




EU/1/24/1802


FABHALTA


Liechtenstein


31.5.2024




EU/1/24/1802


FABHALTA


Norway


29.5.2024




EU/1/23/1788


Filspari


Iceland


14.5.2024




EU/1/23/1788


Filspari


Liechtenstein


30.4.2024




EU/1/23/1788


Filspari


Norway


16.5.2024




EU/1/24/1816


Fluenz


Liechtenstein


30.6.2024




EU/1/24/1816


Fluenz


Norway


6.6.2024




EU/1/24/1827


FRUZAQLA


Liechtenstein


30.6.2024




EU/1/24/1827


FRUZAQLA


Norway


27.6.2024




EU/1/23/1791


Ibuprofen Gen.Orph


Iceland


13.3.2024




EU/1/23/1791


Ibuprofen Gen.Orph


Liechtenstein


29.2.2024




EU/1/23/1791


Ibuprofen Gen.Orph


Norway


23.2.2024




EU/1/24/1807


Incellipan


Iceland


21.5.2024




EU/1/24/1807


Incellipan


Liechtenstein


30.4.2024




EU/1/24/1807


Incellipan


Norway


16.5.2024




EU/2/24/315


Innovax-ND-H5


Liechtenstein


31.5.2024




EU/2/24/315


Innovax-ND-H5


Norway


3.6.2024




EU/1/24/1828


IXCHIQ


Liechtenstein


30.6.2024




EU/1/24/1818


JERAYGO


Liechtenstein


30.6.2024




EU/1/24/1813


Jubbonti


Iceland


3.6.2024




EU/1/24/1813


Jubbonti


Liechtenstein


31.5.2024




EU/1/24/1813


Jubbonti


Norway


22.5.2024




EU/1/23/1744


Krazati


Iceland


12.1.2024




EU/1/23/1744


Krazati


Liechtenstein


31.1.2024




EU/1/23/1744


Krazati


Norway


15.1.2024




EU/2/24/308


Lexylan


Liechtenstein


30.4.2024




EU/2/24/308


Lexylan


Norway


15.5.2024




EU/2/24/311


Lotimax


Liechtenstein


30.4.2024




EU/2/24/311


Lotimax


Norway


15.5.2024




EU/1/24/1798


Lytenava


Iceland


25.6.2024




EU/1/24/1798


Lytenava


Liechtenstein


31.5.2024




EU/1/24/1798


Lytenava


Norway


30.5.2024




EU/1/23/1789


Mevlyq


Iceland


23.2.2024




EU/1/23/1789


Mevlyq


Liechtenstein


29.2.2024




EU/1/23/1789


Mevlyq


Norway


19.2.2024




EU/1/23/1778


Naveruclif


Iceland


12.1.2024




EU/1/23/1778


Naveruclif


Liechtenstein


31.1.2024




EU/1/23/1778


Naveruclif


Norway


10.1.2024




EU/1/24/1804


Neoatricon


Iceland


25.6.2024




EU/1/24/1804


Neoatricon


Liechtenstein


31.5.2024




EU/1/24/1804


Neoatricon


Norway


30.5.2024




EU/1/24/1795


Niapelf


Iceland


5.4.2024




EU/1/24/1795


Niapelf


Liechtenstein


31.3.2024




EU/1/24/1795


Niapelf


Norway


3.4.2024




EU/1/24/1803


Nintedanib Accord


Iceland


15.5.2024




EU/1/24/1803


Nintedanib Accord


Liechtenstein


30.4.2024




EU/1/24/1803


Nintedanib Accord


Norway


29.4.2024




EU/2/23/304


Nobivac LoVo L4


Norway


11.3.2024




EU/2/24/309


Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS


Liechtenstein


31.5.2024




EU/2/24/309


Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS


Norway


15.5.2024




EU/1/24/1822


Obgemsa


Liechtenstein


30.6.2024




EU/1/23/1782


Omjjara


Iceland


21.2.2024




EU/1/23/1782


Omjjara


Liechtenstein


31.1.2024




EU/1/23/1782


Omjjara


Norway


29.1.2024




EU/1/24/1817


Omlyclo


Iceland


3.6.2024




EU/1/24/1817


Omlyclo


Liechtenstein


31.5.2024




EU/1/24/1817


Omlyclo


Norway


30.5.2024




EU/1/23/1785


Pomalidomide Viatris


Iceland


19.3.2024




EU/1/23/1785


Pomalidomide Viatris


Liechtenstein


29.2.2024




EU/1/23/1785


Pomalidomide Viatris


Norway


22.3.2024




EU/1/24/1801


Pyzchiva


Iceland


16.5.2024




EU/1/24/1801


Pyzchiva


Liechtenstein


30.4.2024




EU/1/24/1801


Pyzchiva


Norway


29.4.2024




EU/1/23/1783


Qalsody


Iceland


25.6.2024




EU/1/23/1783


Qalsody


Liechtenstein


31.05.2024




EU/1/23/1783


Qalsody


Norway


04.6.2024




EU/2/24/314


RESPIVAC TRT


Liechtenstein


31.5.2024




EU/2/24/314


RESPIVAC TRT


Norway


20.6.2024




EU/1/23/1779


Rimmyrah


Iceland


12.1.2024




EU/1/23/1779


Rimmyrah


Liechtenstein


31.1.2024




EU/1/23/1779


Rimmyrah


Norway


16.1.2024




EU/1/23/1780


Rystiggo


Iceland


10.1.2024




EU/1/23/1780


Rystiggo


Liechtenstein


31.1.2024




EU/1/23/1780


Rystiggo


Norway


10.1.2024




EU/1/24/1793


Ryzneuta


Iceland


5.4.2024




EU/1/24/1793


Ryzneuta


Liechtenstein


31.3.2024




EU/1/24/1793


Ryzneuta


Norway


26.3.2024




EU/1/23/1786


Skyclarys


Iceland


11.3.2024




EU/1/23/1786


Skyclarys


Liechtenstein


29.2.2024




EU/1/23/1786


Skyclarys


Norway


19.2.2024




EU/1/23/1781


Spexotras


Iceland


16.1.2024




EU/1/23/1781


Spexotras


Liechtenstein


31.1.2024




EU/1/23/1781


Spexotras


Norway


16.1.2024




EU/1/24/1797


Tizveni


Iceland


3.6.2024




EU/1/24/1797


Tizveni


Liechtenstein


30.4.2024




EU/1/24/1797


Tizveni


Norway


29.4.2024




EU/1/24/1825


Tofidence


Liechtenstein


30.6.2024




EU/2/24/312


Trilocur


Liechtenstein


31.5.2024




EU/2/24/312


Trilocur


Norway


15.5.2024




EU/2/24/313


Trilorale


Liechtenstein


31.5.2024




EU/2/24/313


Trilorale


Norway


15.5.2024




EU/1/24/1820


Truqap


Liechtenstein


30.6.2024




EU/1/24/1820


Truqap


Norway


24.6.2024




EU/1/23/1784


Uzpruvo


Iceland


10.1.2024




EU/1/23/1784


Uzpruvo


Liechtenstein


31.1.2024




EU/1/23/1784


Uzpruvo


Norway


11.1.2024




EU/1/23/1790


Velsipity


Iceland


13.3.2024




EU/1/23/1790


Velsipity


Liechtenstein


29.2.2024




EU/1/23/1790


Velsipity


Norway


21.2.2024




EU/1/24/1792


Voydeya


Iceland


17.5.2024




EU/1/24/1792


Voydeya


Liechtenstein


30.4.2024




EU/1/24/1792


Voydeya


Norway


29.4.2024




EU/1/24/1823


Wezenla


Liechtenstein


30.6.2024




EU/1/24/1812


Wyost


Iceland


25.6.2024




EU/1/24/1812


Wyost


Liechtenstein


31.5.2024




EU/1/24/1812


Wyost


Norway


27.5.2024




EU/1/24/1800


ZYNYZ


Iceland


15.5.2024




EU/1/24/1800


ZYNYZ


Liechtenstein


30.4.2024




EU/1/24/1800


ZYNYZ


Norway


29.4.2024









ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2024:








EU-Number


Product


Country


Date of authorisation




EU/1/21/1539


Abecma


Liechtenstein


31.3.2024




EU/1/21/1539


Abecma


Norway


4.4.2024




EU/1/18/1264


Alunbrig


Norway


17.1.2024




EU/1/19/1368


Ambrisentan Mylan


Iceland


9.4.2024




EU/1/19/1368


Ambrisentan Mylan


Liechtenstein


31.3.2024




EU/1/19/1368


Ambrisentan Mylan


Norway


3.4.2024




EU/2/19/239


Baycox Iron


Liechtenstein


31.3.2024




EU/2/19/239


Baycox Iron


Norway


4.4.2024




EU/1/20/1474


BLENREP


Liechtenstein


29.2.2024




EU/2/13/158


Bravecto


Norway


27.6.2024




EU/1/22/1648


CARVYKTI


Iceland


19.3.2024




EU/1/22/1648


CARVYKTI


Liechtenstein


31.3.2024




EU/1/22/1648


CARVYKTI


Norway


3.4.2024




EU/1/23/1742


Columvi


Liechtenstein


31.5.2024




EU/1/23/1742


Columvi


Norway


13.6.2024




EU/1/19/1365


Cufence


Liechtenstein


31.5.2024




EU/1/19/1365


Cufence


Norway


27.5.2024




EU/1/18/1349


Dectova


Iceland


16.1.2024




EU/1/18/1349


Dectova


Liechtenstein


31.1.2024




EU/1/18/1349


Dectova


Norway


16.1.2024




EU/1/13/875


Deltyba


Iceland


18.3.2024




EU/1/13/875


Deltyba


Liechtenstein


29.2.2024




EU/1/13/875


Deltyba


Norway


2.4.2024




EU/1/19/1373


Doptelet


Iceland


11.3.2024




EU/1/19/1373


Doptelet


Liechtenstein


29.2.2024




EU/1/19/1373


Doptelet


Norway


14.3.2024




EU/1/19/1370


Dovato


Iceland


11.4.2024




EU/1/19/1370


Dovato


Liechtenstein


31.3.2024




EU/1/19/1370


Dovato


Norway


3.4.2024




EU/1/19/1374


Esperoct


Iceland


23.2.2024




EU/1/19/1374


Esperoct


Liechtenstein


29.2.2024




EU/1/19/1374


Esperoct


Norway


16.2.2024




EU/2/18/233


Evant


Norway


4.1.2024




EU/1/18/1326


Flucelvax Tetra


Iceland


10.1.2024




EU/1/18/1326


Flucelvax Tetra


Liechtenstein


31.12.2023 (1)





EU/1/18/1326


Flucelvax Tetra


Norway


11.1.2024




EU/2/19/240


Frontpro


Norway


19.2.2024




EU/1/18/1337


GHRYVELIN


Iceland


16.1.2024




EU/1/18/1337


GHRYVELIN


Liechtenstein


31.1.2024




EU/1/18/1337


GHRYVELIN


Norway


17.1.2024




EU/1/19/1384


Giapreza


Liechtenstein


31.5.2024




EU/1/19/1384


Giapreza


Norway


27.5.2024




EU/1/19/1375


Grasustek


Liechtenstein


31.5.2024




EU/1/19/1375


Grasustek


Norway


27.5.2024




EU/1/14/987


Holoclar


Iceland


18.3.2024




EU/1/14/987


Holoclar


Liechtenstein


24.2.2024




EU/1/14/987


Holoclar


Norway


6.3.2024




EU/1/19/1390


Inbrija


Liechtenstein


30.6.2024




EU/1/19/1390


Inbrija


Norway


25.6.2024




EU/1/21/1538


Jemperli


Liechtenstein


31.12.2023 (1)





EU/1/21/1538


Jemperli


Norway


12.3.2024




EU/1/22/1657


Kinpeygo


Liechtenstein


30.6.2024




EU/1/21/1552


Koselugo


Liechtenstein


30.4.2024




EU/1/12/1552


Koselugo


Norway


7.5.2024




EU/1/19/1383


Lacosamide UCB


Liechtenstein


30.4.2024




EU/1/19/1383


Lacosamide UCB


Norway


10.4.2024




EU/1/19/1355


Lorviqua


Iceland


12.4.2024




EU/1/19/1355


Lorviqua


Liechtenstein


30.4.2024




EU/1/19/1355


Lorviqua


Norway


12.4.2024




EU/1/22/1649


Lunsumio


Liechtenstein


30.4.2024




EU/1/22/1649


Lunsumio


Norway


2.5.2024




EU/1/19/1381


LysaKare


Liechtenstein


30.4.2024




EU/1/19/1381


LysaKare


Norway


16.5.2024




EU/1/23/1741


Lytgobi


Liechtenstein


31.5.2024




EU/1/23/1741


Lytgobi


Norway


5.6.2024




EU/1/18/1348


Mulpleo


Iceland


16.1.2024




EU/1/18/1348


Mulpleo


Liechtenstein


31.1.2024




EU/1/18/1348


Mulpleo


Norway


10.1.2024




EU/1/15/1078


Natpar


Iceland


18.3.2024




EU/1/15/1078


Natpar


Liechtenstein


29.02.2024




EU/1/15/1078


Natpar


Norway


27.2.2024




EU/1/19/1364


NUCEIVA


Liechtenstein


31.5.2024




EU/1/19/1364


NUCEIVA


Norway


30.5.2024




EU/1/18/1345


Ondexxya


Iceland


11.4.2024




EU/1/18/1345


Ondexxya


Liechtenstein


31.3.2024




EU/1/18/1345


Ondexxya


Norway


8.4.2024




EU/1/19/1362


Palynziq


Liechtenstein


30.4.2024




EU/1/19/1362


Palynziq


Norway


16.5.2024




EU/1/16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Liechtenstein


30.4.2024




EU//16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Norway


7.5.2024




EU/1/18/1317


Pazenir


Iceland


10.1.2024




EU/1/18/1317


Pazenir


Liechtenstein


31.1.2024




EU/1/18/1317


Pazenir


Norway


10.1.2024




EU/1/21/1535


Pemazyre


Iceland


18.3.2024




EU/1/21/1535


Pemazyre


Liechtenstein


29.2.2024




EU/1/21/1535


Pemazyre


Norway


6.3.2024




EU/1/19/1379


Posaconazole Accord


Liechtenstein


30.4.2024




EU/1/19/1379


Posaconazole Accord


Norway


12.4.2024




EU/1/19/1380


Posaconazole AHCL


Iceland


17.4.2024




EU/1/19/1380


Posaconazole AHCL


Liechtenstein


30.4.2024




EU/1/19/1380


Posaconazole AHCL


Norway


16.4.2024




EU/2/19/237


ReproCyc ParvoFLEX


Liechtenstein


31.3.2024




EU/2/19/237


ReproCyc ParvoFLEX


Norway


4.4.2024




EU/1/20/1527


Retsevmo


Iceland


10.1.2024




EU/1/20/1527


Retsevmo


Liechtenstein


31.1.2024




EU/1/20/1527


Retsevmo


Norway


16.1.2024




EU/1/20/1460


Rozlytrek


Liechtenstein


31.5.2024




EU/1/20/1460


Rozlytrek


Norway


28.5.2024




EU/1/19/1369


Sixmo


Iceland


11.4.2024




EU/1/19/1369


Sixmo


Liechtenstein


31.3.2024




EU/1/19/1369


Sixmo


Norway


3.4.2024




EU/1/19/1361


Skyrizi


Iceland


16.1.2024




EU/1/19/1361


Skyrizi


Liechtenstein


31.1.2024




EU/1/19/1361


Skyrizi


Norway


16.1.2024




EU/2/19/248


Stelfonta


Norway


4.3.2024




EU/1/19/1372


Striascan


Iceland


20.3.2024




EU/1/19/1372


Striascan


Liechtenstein


31.3.2024




EU/1/19/1372


Striascan


Norway


26.3.2024




EU/1/23/1748


TALVEY


Liechtenstein


30.6.2024




EU/1/23/1748


TALVEY


Norway


25.6.2024




EU/1/19/1377


Talzenna


Liechtenstein


30.4.2024




EU/1/19/1377


Talzenna


Norway


22.4.2024




EU/1/20/1492


Tecartus


Norway


16.1.2024




EU/1/22/1675


TECVAYLI


Liechtenstein


30.6.2024




EU/1/22/1675


TECVAYLI


Norway


25.6.2024




EU/1/18/1351


Trecondi


Iceland


11.1.2024




EU/1/18/1351


Trecondi


Liechtenstein


31.1.2024




EU/1/18/1351


Trecondi


Norway


10.1.2024




EU/1/19/1371


Ultomiris


Liechtenstein


30.4.2024




EU/1/19/1371


Ultomris


Norway


5.6.2024




EU/2/14/168


Versican Plus Pi


Liechtenstein


30.6.2024




EU/2/14/168


Versican Plus Pi


Norway


25.6.2024




EU/1/19/1360


Waylivra


Iceland


20.3.2024




EU/1/19/1360


Waylivra


Liechtenstein


31.3.2024




EU/1/19/1360


Waylivra


Norway


3.4.2024




EU/1/19/1399


Xospata


Liechtenstein


30.6.2024




EU/1/19/1366


Xromi


Liechtenstein


31.5.2024




EU/1/19/1366


Xromi


Norway


16.5.2024




EU/1/14/938


Zydelig


Liechtenstein


30.6.2024






(1)  Authorisation was unintentionally omitted from the list for the 2nd half of 2023.





ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2024:








EU-Number


Product


Country


Date of authorisation




EU/1/13/882/009-010


ABILIFY MAINTENA


Iceland


11.4.2024




EU/1/13/882/009-010


ABILIFY MAINTENA


Norway


30.4.2024




EU/1/16/1164/010-022


AMGEVITA


Iceland


27.6.2024




EU/1/16/1164/010-022


AMGEVITA


Norway


23.5.2024




EU/1/20/1528/025


Comirnaty


Iceland


28.6.2024




EU/1/20/1528/025-026


Comirnaty


Norway


28.5.2024




EU/1/12/797/003


Eylea


Iceland


10.1.2024




EU/1/12/797/003


Eylea


Norway


10.1.2024




EU/1/12/782/010-011


Kalydeco


Iceland


19.6.2024




EU/1/12/782/010-011


Kalydeco


Norway


30.4.2024




EU/1/21/1603/004


Lumykras


Iceland


28.6.2024




EU/1/21/1603/004


Lumykras


Norway


22.5.2024




EU/1/18/1315/003-004


Mektovi


Norway


17.6.2024




EU/1/22/1685/049-060


Mounjaro


Iceland


14.6.2024




EU/1/22/1685/049-060


Mounjaro


Norway


2.5.2024




EU/1/17/1231/003


Ocrevus


Norway


20.6.2024




EU/1/21/1251/012-013


Ozempic


Norway


17.6.2024




EU/1/19/1361/006


Skyrizi


Iceland


16.1.2024




EU/1/19/1377/007


Talzenna


Iceland


16.1.2024




EU/1/19/1377/007


Talzenna


Norway


11.1.2024




EU/1/17/1220/003


Tecentriq


Iceland


17.1.2024




EU/1/17/1220/003


Tecentriq


Norway


16.1.2024




EU/1/10/622/004


Tepadina


Iceland


8.4.2024




EU/1/10/622/004


Tepadina


Norway


3.4.2024




EU/1/22/1693/005-012


Teriflunomide Accord


Iceland


27.6.2024




EU/1/22/1693/005-012


Teriflunomide Accord


Norway


3.6.2024




EU/1/15/1083/012-013


Uptravi


Iceland


11.4.2024




EU/1/15/1083/012-013


Uptravi


Norway


5.4.2024




EU/1/17/1179/011


Veltassa


Iceland


10.1.2024




EU/1/17/1179/011


Veltassa


Norway


11.1.2024




EU/1/98/077/026-029


Viagra


Iceland


23.2.2024




EU/1/98/077/026-029


Viagra


Norway


19.2.2024




EU/1/21/1608/012


Wegovy


Norway


17.6.2024









ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2024:








EU-Number


Product


Country


Date of withdrawal




EU/2/10/118


Activyl


Norway


24.1.2024




EU/1/18/1292


Apealea


Iceland


23.2.2024




EU/1/18/1292


Apealea


Liechtenstein


29.2.2024




EU/1/18/1292


Apealea


Norway


22.2.2024




EU/1/20/1474


Blenrep


Iceland


16.4.2024




EU/1/20/1474


Blenrep


Liechtenstein


29.2.2024




EU/1/20/1474


Blenrep


Norway


28.2.2024




EU/2/17/218


Bovilis Blue-8


Iceland


12.4.2024




EU/2/17/218


Bovilis Blue-8


Liechtenstein


31.3.2024




EU/2/17/218


Bovilis Blue-8


Norway


9.4.2024




EU/1/09/558


Clopidogrel BGR


Norway


23.1.2024




EU/1/12/784


Cuprymina


Iceland


21.2.2024




EU/1/12/784


Cuprymina


Liechtenstein


31.1.2024




EU/1/12/784


Cuprymina


Norway


12.3.2024




EU/1/22/1711


Dimethyl fumarate Accord


Iceland


9.1.2024




EU/1/22/1711


Dimethyl fumarate Accord


Liechtenstein


31.12.2023 (1)





EU/1/22/1634


Dimethyl fumarate Mylan


Iceland


9.1.2024




EU/1/22/1634


Dimethyl fumarate Mylan


Liechtenstein


31.12.2023 (1)





EU/1/22/1637


Dimethyl fumarate Neuraxpharm


Iceland


9.1.2024




EU/1/22/1637


Dimethyl fumarate Neuraxpharm


Liechtenstein


31.12.2023 (1)





EU/1/22/1635


Dimethyl fumarate Polpharma


Iceland


9.1.2024




EU/1/22/1635


Dimethyl fumarate Polpharma


Liechtenstein


31.12.2023 (1)





EU/1/22/1702


Dimethyl fumarate Teva


Iceland


9.1.2024




EU/1/22/1702


Dimethyl fumarate Teva


Liechtenstein


31.12.2023 (1)





EU/2/20/268


Enteroporc Coli


Iceland


12.4.2024




EU/2/20/268


Enteroporc Coli


Liechtenstein


31.3.2024




EU/2/20/268


Enteroporc Coli


Norway


11.4.2024




EU/1/20/1520


Lenalidomide Krka d.d. Novo mesto


Iceland


11.1.2024




EU/1/20/1520


Lenalidomide Krka d.d. Novo mesto


Liechtenstein


30.9.2023 (1)





EU/1/20/1520


Lenalidomide Krka d.d. Novo mesto


Norway


23.1.2024




EU/1/18/1290


Nityr


Liechtenstein


30.6.2024




EU/1/20/1499


Onbevzi


Norway


24.1.2024




EU/1/18/1283


Pemetrexed Krka


Liechtenstein


30.6.2024




EU/1/12/764


Pixuvri


Iceland


18.6.2024




EU/1/12/764


Pixuvri


Liechtenstein


30.9.2023 (1)





EU/1/12/764


Pixuvri


Norway


12.6.2024




EU/1/96/018


Rapilysin


Iceland


21.2.2024




EU/1/96/018


Rapilysin


Liechtenstein


31.1.2024




EU/1/96/018


Rapilysin


Norway


8.2.2024




EU/1/99/110


Sustiva


Iceland


21.2.2024




EU/1/99/110


Sustiva


Liechtenstein


29.2.2024




EU/1/99/110


Sustiva


Norway


22.2.2024




EU/1/11/719


Telmisartan Teva Pharma


Liechtenstein


30.4.2024




EU/1/11/719


Telmisartan Teva Pharma


Norway


21.5.2024




EU/1/22/1639


Truvelog Mix 30


Iceland


22.2.2024




EU/1/22/1639


Truvelog Mix 30


Liechtenstein


31.1.2024




EU/1/22/1639


Truvelog Mix 30


Norway


22.2.2024




EU/1/21/1529


Vaxzevria


Iceland


2.5.2024




EU/1/21/1529


Vaxzevria


Liechtenstein


31.3.2024




EU/1/21/1529


Vaxzevria


Norway


9.4.2024




EU/1/21/1580


VidPrevtyn Beta


Iceland


19.3.2024




EU/1/21/1580


VidPrevtyn Beta


Liechtenstein


31.3.2024




EU/1/21/1580


VidPrevtyn Beta


Norway


4.4.2024




EU/1/12/759


Zoledronic acid Actavis


Iceland


20.3.2024




EU/1/12/759


Zoledronic acid Actavis


Liechtenstein


31.3.2024




EU/1/12/759


Zoledronic acid Actavis


Norway


4.4.2024




EU/1/12/800


Zoledronic acid Hospira


Iceland


19.3.2024




EU/1/12/800


Zoledronic acid Hospira


Liechtenstein


29.2.2024






(1)  Authorisation was unintentionally omitted from the list for the 2nd half of 2023.





ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2024:








EU-Number


Product


Country


Date of suspension




 


 


 


 




 


 


 


 




 


 


 


 







ELI: http://data.europa.eu/eli/C/2025/950/oj
ISSN 1977-091X (electronic edition)